JP2005511656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511656A5 JP2005511656A5 JP2003548823A JP2003548823A JP2005511656A5 JP 2005511656 A5 JP2005511656 A5 JP 2005511656A5 JP 2003548823 A JP2003548823 A JP 2003548823A JP 2003548823 A JP2003548823 A JP 2003548823A JP 2005511656 A5 JP2005511656 A5 JP 2005511656A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- group
- alkylene
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 60
- 125000000217 alkyl group Chemical group 0.000 claims 53
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 125000002947 alkylene group Chemical group 0.000 claims 31
- 125000003118 aryl group Chemical group 0.000 claims 24
- -1 indrone Chemical compound 0.000 claims 22
- 125000001072 heteroaryl group Chemical group 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 229910052739 hydrogen Inorganic materials 0.000 claims 18
- 239000001257 hydrogen Substances 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000012453 solvate Substances 0.000 claims 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 8
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000004122 cyclic group Chemical group 0.000 claims 8
- 125000004076 pyridyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 208000030814 Eating disease Diseases 0.000 claims 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 239000002830 appetite depressant Substances 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 235000014632 disordered eating Nutrition 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 5
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 4
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 4
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 4
- 239000012964 benzotriazole Substances 0.000 claims 4
- 125000002993 cycloalkylene group Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 239000000883 anti-obesity agent Substances 0.000 claims 3
- 229940125710 antiobesity agent Drugs 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032841 Bulimia Diseases 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 1
- SXKBTDJJEQQEGE-UHFFFAOYSA-N 3-(3,5-dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonic acid [4-(thiazol-2-ylsulfamoyl)-phenyl]-amide Chemical compound CCC=1OC2=CC(S(=O)(=O)NC=3C=CC(=CC=3)S(=O)(=O)NC=3SC=CN=3)=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 SXKBTDJJEQQEGE-UHFFFAOYSA-N 0.000 claims 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 1
- QTQMRBZOBKYXCG-MHZLTWQESA-N GW 1929 Chemical compound N([C@@H](CC1=CC=C(C=C1)OCCN(C)C=1N=CC=CC=1)C(O)=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 QTQMRBZOBKYXCG-MHZLTWQESA-N 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 239000003288 aldose reductase inhibitor Substances 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229960001761 chlorpropamide Drugs 0.000 claims 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004474 heteroalkylene group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 0 CC(C1)(C=CC(*=C)=C1O)NC(N(C(CC1)CC=C1c1cc(C#N)ccc1)N(C)C)=O Chemical compound CC(C1)(C=CC(*=C)=C1O)NC(N(C(CC1)CC=C1c1cc(C#N)ccc1)N(C)C)=O 0.000 description 6
- LZAMLBFWTLFDKM-RXMQYKEDSA-N CC(C)N[C@@H](C)O Chemical compound CC(C)N[C@@H](C)O LZAMLBFWTLFDKM-RXMQYKEDSA-N 0.000 description 1
- WGLCVIHKXDMDGV-NVNXTCNLSA-N CCCCC1(CC/C=C(/CC=C2)\C=C2C#N)CC1 Chemical compound CCCCC1(CC/C=C(/CC=C2)\C=C2C#N)CC1 WGLCVIHKXDMDGV-NVNXTCNLSA-N 0.000 description 1
- FATOUWYXFUDWPE-UHFFFAOYSA-N CN1CN(CCCNC(Nc(cc2Cl)ccc2F)=O)CC1 Chemical compound CN1CN(CCCNC(Nc(cc2Cl)ccc2F)=O)CC1 FATOUWYXFUDWPE-UHFFFAOYSA-N 0.000 description 1
- QVYQPUPDVBARSC-MKWMUHEDSA-N N#CC(C1)CC=CC1C(C1)C(CC2)[C@H]1[C@@H]2N(CN(CC1)CC1O)C(Nc(cc1C(CCF)F)ccc1F)=O Chemical compound N#CC(C1)CC=CC1C(C1)C(CC2)[C@H]1[C@@H]2N(CN(CC1)CC1O)C(Nc(cc1C(CCF)F)ccc1F)=O QVYQPUPDVBARSC-MKWMUHEDSA-N 0.000 description 1
- VBOMXJWPUDJWDX-UHFFFAOYSA-N N=C(CCC1)CC1C(CC1)CCC1N(CCN1CCCC1)C(NC(CCC1F)CC1C(F)(F)F)O Chemical compound N=C(CCC1)CC1C(CC1)CCC1N(CCN1CCCC1)C(NC(CCC1F)CC1C(F)(F)F)O VBOMXJWPUDJWDX-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33726201P | 2001-12-04 | 2001-12-04 | |
| US39985302P | 2002-07-31 | 2002-07-31 | |
| PCT/US2002/038408 WO2003047568A1 (en) | 2001-12-04 | 2002-12-03 | N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009118103A Division JP2009235076A (ja) | 2001-12-04 | 2009-05-14 | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511656A JP2005511656A (ja) | 2005-04-28 |
| JP2005511656A5 true JP2005511656A5 (enExample) | 2006-03-09 |
| JP4330996B2 JP4330996B2 (ja) | 2009-09-16 |
Family
ID=26990617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003548823A Expired - Fee Related JP4330996B2 (ja) | 2001-12-04 | 2002-12-03 | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 |
| JP2009118103A Pending JP2009235076A (ja) | 2001-12-04 | 2009-05-14 | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009118103A Pending JP2009235076A (ja) | 2001-12-04 | 2009-05-14 | 肥満の処置のためのｍｃｈアンタゴニストとしてのｎ−アリール−ｎ’−アリールシクロアルキル−尿素−誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7348328B2 (enExample) |
| EP (1) | EP1453501B1 (enExample) |
| JP (2) | JP4330996B2 (enExample) |
| KR (1) | KR20050044664A (enExample) |
| CN (1) | CN1617718A (enExample) |
| AR (1) | AR037621A1 (enExample) |
| AT (1) | ATE404190T1 (enExample) |
| AU (1) | AU2002348269A1 (enExample) |
| CA (1) | CA2468967A1 (enExample) |
| DE (1) | DE60228317D1 (enExample) |
| ES (1) | ES2312637T3 (enExample) |
| HU (1) | HUP0500034A2 (enExample) |
| IL (1) | IL162311A0 (enExample) |
| MX (1) | MXPA04005503A (enExample) |
| PE (1) | PE20030680A1 (enExample) |
| TW (1) | TW200302719A (enExample) |
| WO (1) | WO2003047568A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7304065B2 (en) | 2003-10-01 | 2007-12-04 | The Procter & Gamble Company | Melanin concentrating hormone antagonists |
| WO2005034947A1 (en) * | 2003-10-02 | 2005-04-21 | Schering Corporation | Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| DE102004003811A1 (de) * | 2004-01-25 | 2005-08-11 | Aventis Pharma Deutschland Gmbh | Substituierte N-Cyclohexylimidazolinone, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| EP1773822B1 (en) * | 2004-07-16 | 2009-06-17 | Shering Corporation | Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| CA2583454A1 (en) * | 2004-10-12 | 2006-04-27 | Pharmacopeia Drug Discovery, Inc. | Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| BRPI0518241A (pt) * | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| AU2005305036B2 (en) * | 2004-11-01 | 2011-03-10 | Amylin Pharmaceuticals, Llc | Treatment of obesity and related disorders |
| US20090264650A1 (en) * | 2005-03-31 | 2009-10-22 | Nobuo Cho | Prophylactic/Therapeutic Agent for Diabetes |
| US7799943B2 (en) * | 2005-06-24 | 2010-09-21 | Rohm And Haas Company | Method for promoting Michael addition reactions |
| RU2008107336A (ru) | 2005-07-27 | 2009-09-10 | Дов Фармасьютикал, Инк. (Us) | Новые 1-арил-з-азабицикло{3.1.0.} гексаны: получение и применение для лечения психоневрологических расстройств |
| US20080045725A1 (en) | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
| US20080269348A1 (en) * | 2006-11-07 | 2008-10-30 | Phil Skolnick | Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use |
| US8138377B2 (en) | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| US8030495B2 (en) * | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| EP2036578A1 (en) * | 2007-09-13 | 2009-03-18 | Bayer Schering Pharma Aktiengesellschaft | Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| CN102875385A (zh) * | 2012-10-18 | 2013-01-16 | 浙江大学 | N,n-二异丙基乙胺的合成方法 |
| WO2018026890A1 (en) | 2016-08-03 | 2018-02-08 | Cymabay Therapeutics | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| AU2020308862A1 (en) * | 2019-06-28 | 2022-01-20 | Research Triangle Institute | Urea derivatives as CB1 allosteric modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW209868B (enExample) | 1991-04-04 | 1993-07-21 | Yoshitomi Pharmaceutical | |
| US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| CA2273102A1 (en) * | 1996-12-03 | 1998-06-11 | Banyu Pharmaceutical Co., Ltd. | Urea derivatives |
| CN1311773A (zh) * | 1998-06-08 | 2001-09-05 | 先灵公司 | 神经肽y5受体拮抗剂 |
| GB0010757D0 (en) * | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-12-03 WO PCT/US2002/038408 patent/WO2003047568A1/en not_active Ceased
- 2002-12-03 DE DE60228317T patent/DE60228317D1/de not_active Expired - Lifetime
- 2002-12-03 AR ARP020104668A patent/AR037621A1/es unknown
- 2002-12-03 IL IL16231102A patent/IL162311A0/xx unknown
- 2002-12-03 AU AU2002348269A patent/AU2002348269A1/en not_active Abandoned
- 2002-12-03 US US10/308,782 patent/US7348328B2/en not_active Expired - Fee Related
- 2002-12-03 EP EP02782401A patent/EP1453501B1/en not_active Expired - Lifetime
- 2002-12-03 MX MXPA04005503A patent/MXPA04005503A/es not_active Application Discontinuation
- 2002-12-03 AT AT02782401T patent/ATE404190T1/de not_active IP Right Cessation
- 2002-12-03 CA CA002468967A patent/CA2468967A1/en not_active Abandoned
- 2002-12-03 HU HU0500034A patent/HUP0500034A2/hu unknown
- 2002-12-03 CN CNA028277554A patent/CN1617718A/zh active Pending
- 2002-12-03 PE PE2002001165A patent/PE20030680A1/es not_active Application Discontinuation
- 2002-12-03 KR KR1020047008490A patent/KR20050044664A/ko not_active Withdrawn
- 2002-12-03 ES ES02782401T patent/ES2312637T3/es not_active Expired - Lifetime
- 2002-12-03 TW TW091135038A patent/TW200302719A/zh unknown
- 2002-12-03 JP JP2003548823A patent/JP4330996B2/ja not_active Expired - Fee Related
-
2009
- 2009-05-14 JP JP2009118103A patent/JP2009235076A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511656A5 (enExample) | ||
| JP2005510563A5 (enExample) | ||
| JP2005507918A5 (enExample) | ||
| CA2464130A1 (en) | Mch antagonists for the treatment of obesity | |
| CA2467857A1 (en) | Piperidine-based mch antagonists for treatment of obesity and cns disorders | |
| JP2005532392A5 (enExample) | ||
| CA2454830A1 (en) | Substituted urea neuropeptide y y5 receptor antagonists | |
| JP2010538076A5 (enExample) | ||
| HRP20141048T1 (hr) | Spojevi, pripravci i metode | |
| CA2441239A1 (en) | Mch antagonists and their use in the treatment of obesity | |
| JP2011527334A5 (enExample) | ||
| MY136034A (en) | New medicaments for the treatment of chronic obstructive pulmonary disease | |
| CN1466569A (zh) | 新型3-取代的脲衍生物及其药学应用 | |
| EP1509509A1 (en) | Glucagon antagonists/inverse agonists | |
| JP2002501049A5 (enExample) | ||
| TW200407327A (en) | Calcitonin gene related peptide receptor antagonists | |
| JP2005539088A5 (enExample) | ||
| JP2008513504A5 (enExample) | ||
| RU2005139525A (ru) | N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы | |
| CN1137755A (zh) | 用作α-2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹喔啉化合物 | |
| JP2005535641A5 (enExample) | ||
| CN1274288A (zh) | 含肽的α－酮酰胺半胱氨酸和丝氨酸蛋白酶抑制剂 | |
| US7141590B2 (en) | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | |
| JP2007502817A5 (enExample) | ||
| JP2008516968A5 (enExample) |